Is Checkpoint Inhibitor Price Competition Coming In The Oncology Space? Historically, as new anti-PD-1/PD-L1 immune checkpoint inhibitors have gained approval price competition hasn't been a factor. This could change with the expected approval of several new drugs. Price competition among checkpoint inhibitors may be coming to the cancer space.